Bicara Therapeutics/$BCAX
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Bicara Therapeutics
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
Ticker
$BCAX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
55
Website
BCAX Metrics
BasicAdvanced
$606M
-
-$3.05
-
-
Price and volume
Market cap
$606M
52-week high
$28.09
52-week low
$7.80
Average daily volume
539K
Financial strength
Current ratio
24.621
Quick ratio
24.167
Total debt to equity
0.129
Profitability
EBITDA (TTM)
-108.741
Effective tax rate (TTM)
-0.28%
Management effectiveness
Return on equity (TTM)
-27.26%
Valuation
Price to book
1.32
Price to tangible book (TTM)
1.32
Price to free cash flow (TTM)
-3.805
Free cash flow yield (TTM)
-26.28%
Free cash flow per share (TTM)
-2.92
Growth
Earnings per share change (TTM)
-96.69%
Bulls say / Bears say
Bicara Therapeutics successfully closed its initial public offering in September 2024, raising $362 million, providing substantial capital to advance its pipeline of bifunctional therapies for solid tumors. (biospace.com)
Institutional investors, such as Foresite Capital Management VI LLC, have shown confidence in Bicara by purchasing significant shares, with Foresite acquiring 950,000 shares valued at approximately $16.5 million in April 2025. (marketbeat.com)
Analysts have maintained a positive outlook on Bicara, with HC Wainwright issuing a 'buy' rating and a price target of $41.00 in May 2025, indicating potential upside from the current stock price. (americanbankingnews.com)
Following the release of interim data from a clinical trial in May 2025, Bicara's stock plummeted 30% in after-hours trading, reflecting investor concerns over the trial results. (investing.com)
HC Wainwright reduced its price target for Bicara from $44.00 to $41.00 in May 2025, suggesting tempered expectations for the company's stock performance. (americanbankingnews.com)
The expiration of Bicara's lock-up period in March 2025 allowed insiders and major shareholders to sell their shares, potentially increasing stock volatility and downward pressure on the stock price. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bicara Therapeutics stock?
Bicara Therapeutics (BCAX) has a market cap of $606M as of August 01, 2025.
What is the P/E ratio for Bicara Therapeutics stock?
The price to earnings (P/E) ratio for Bicara Therapeutics (BCAX) stock is 0 as of August 01, 2025.
Does Bicara Therapeutics stock pay dividends?
No, Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Bicara Therapeutics dividend payment date?
Bicara Therapeutics (BCAX) stock does not pay dividends to its shareholders.
What is the beta indicator for Bicara Therapeutics?
Bicara Therapeutics (BCAX) does not currently have a Beta indicator.